September 18, 2024

SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Despite the mechanistic potential of sodium-glucose cotransporter 2 inhibitor (SGLT2i) to improve neurologic outcomes, the efficacy of SGLT2i in neurodegenerative disorders among patients with type 2 diabetes is not well established. This population-based cohort study aimed to investigate the association of SGLT2i use with risks of incident dementia and Parkinson disease (PD) in patients with type 2 diabetes.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Kim et al. (Wed,) studied this question.

synapsesocial.com/papers/68e580d4b6db64358751e860 https://doi.org/https://doi.org/10.1212/wnl.0000000000209805

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease2022 · 81 citations
2The role of type 2 diabetes in neurodegeneration2015 · 273 citations
3Dementia prevention, intervention, and care2017 · 6,204 citations
4The competing risk of death and selective survival cannot fully explain the inverse cancer‐dementia association2020 · 31 citations
5Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke2023 · 36 citations

Preguntar a la IA

Me gusta

Guardar